PTCT — PTC Therapeutics, Inc.

Summary of PTC Therapeutics Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: Total net product and royalty revenue reached $263 million, with Sephience contributing $92 million.
• Full Year 2025 Revenue: Total net product and royalty revenue was $831 million, exceeding guidance of $750 million to $800 million. Sephience generated $111 million since its launch.
• Operating Expenses: Non-GAAP R&D and SG&A expenses totaled $728 million for 2025, below the guidance of $730 million to $760 million.
• Cash Position: Ended 2025 with $1.95 billion in cash, following the sale of the remaining Evrysdi royalty for $240 million.

2. Strategic Updates and Business Highlights

• Sephience Launch: The product received global approvals in the U.S., EU, Japan, and other countries, showing strong uptake across all patient segments. By the end of 2025, 946 patients were on commercial therapy.
• R&D Pipeline Advances: Positive results from the Phase II PIVOT-HD study of votoplam were reported, and several early-stage programs from the RNA splicing platform are progressing.
• Market Expansion: Plans to expand Sephience into 20-30 countries by the end of 2026, with a focus on increasing penetration in existing markets and launching in new ones, including Japan and Brazil.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected product revenue between $700 million and $800 million, representing 19% to 36% growth year-over-year, primarily from Sephience.
• Expense Guidance: Non-GAAP R&D and SG&A expenses projected at $680 million to $720 million for 2026.
• Cash Flow Breakeven: The company anticipates reaching cash flow breakeven in 2026, supported by strong revenue growth and disciplined expense management.

4. Bad News, Challenges, or Points of Concern

• Competitive Pressures: The DMD franchise faces headwinds from increased generic competition, which may impact revenue.
• Vatiquinone Development: The FDA has requested an additional study for vatiquinone following a Complete Response Letter (CRL), which may delay its approval timeline.
• Market Dynamics: While Sephience has shown strong early adoption, the company must continue to engage the remaining 20% of centers of excellence that have not yet prescribed the drug.

5. Notable Q&A Insights

• Sephience Sales Expectations: Management indicated that the majority of 2026 revenue will come from Sephience, with expectations for contributions from international markets to ramp up later in the year.
• Patient Engagement: There is a notable increase in "lost to follow-up" patients seeking treatment, driven by social media awareness and positive patient experiences.
• Reimbursement Dynamics: Favorable payer policies have emerged, with many plans offering limited prior authorization requirements and extended refill periods.
• Huntington's Program: Novartis will lead the Phase III study for votoplam, with potential for accelerated approval based on interim analysis results.

Overall, PTC Therapeutics demonstrated a strong performance in 2025, particularly with the Sephience launch, while also navigating challenges in its broader pipeline and competitive landscape. The outlook for 2026 remains positive, with significant revenue growth anticipated.